The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review.

Authors:
Younossi ZM; Golabi P; Paik JM; Paik JM; Henry A and 2 more

Journal:
Hepatology

Publication Year: 2023

DOI:
10.1097/HEP.0000000000000004

PMCID:
PMC10026948

PMID:
36626630

View on PubMed View on PMC View Publisher
Journal Information

Full Title: Hepatology

Abbreviation: Hepatology

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Gastroenterology

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Related Papers from Same Journal
A global action agenda for turning the tide on fatty liver disease.
Lazarus JV; Mark HE; Allen AM and 44 more (2023) - Transparency Score: 3/6
c-Rel-dependent Chk2 signaling regulates the DNA damage response limiting hepatocarcinogenesis.
Leslie J; Hunter JE; Collins A and 15 more (2023) - Transparency Score: 3/6
Effect of tenofovir-based HIV pre-exposure prophylaxis against HBV infection in men who have sex wi…
Mizushima D; Takano M; Aoki T and 7 more (2023) - Transparency Score: 3/6
Emergence of resistance-associated variants during sofosbuvir treatment in chronically infected hep…
Gömer A; Klöhn M; Jagst M and 12 more (2023) - Transparency Score: 3/6
Enhanced mitochondrial activity reshapes a gut microbiota profile that delays NASH progression.
Juárez-Fernández M; Goikoetxea-Usandizaga N; Goikoetxea-Usandizaga N and 18 more (2023) - Transparency Score: 4/6
View All Papers from This Journal
Transparency Score
3/6
50.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"CONFLICT OF INTEREST Dr Zobair M. Younossi consults for BMS, Gilead, AbbVie, Abbott, Novo Nordisk, Madrigal, Merck, Siemens, and Intercept. The remaining authors have no conflicts to report."

Evidence found in paper:

"Funding : This study was funded by Inova Medicine Service Line."

Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025